CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global biopharmaceutical company focused on the discovery and development of precision genetic medicines for the treatment of rare neuromuscular and other rare diseases, will ring Nasdaq’s Opening Bell today in recognition of World Duchenne Awareness Day (WDAD), an observance recognized annually around the world on September 7.

“We are fully committed to our mission of bringing a longer, richer life to patients with Duchenne muscular dystrophy. Along with other healthcare companies dedicated to fighting this disease, we believe we may stand at the threshold of a new frontier, unlocking the potential of precision genetic medicine to make a profound difference in the lives of individuals living with rare genetic disease,” said Doug Ingram, Sarepta’s president and chief executive officer.

“This year’s World Duchenne Awareness Day is focused on standards of care and efforts to raise awareness of this topic globally through education. The Duchenne community and healthcare providers have focused on enhancing quality care for individuals with Duchenne, including clinical and medical care, but also social support, as well.” Mr. Ingram explained, “On behalf of our global team at Sarepta, I would like to thank all those who advocate for Duchenne awareness and dedicate themselves to enhancing quality of care. We remain united with the global Duchenne community to do all possible to put an end to the damage caused by this disease.”

A devastating and incurable muscle-wasting disease, Duchenne is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Progressive muscle weakness in the lower limbs spreads to the arms, neck and other areas of the body. The condition is universally fatal, and death usually occurs before the age of 30 generally due to respiratory or cardiac failure.

About Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.

Forward-Looking Statements

This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding Sarepta being fully committed to its mission of bringing a longer, richer life to patients with DMD; Sarepta’s belief that it may stand at the threshold of a new frontier, unlocking the potential of precision genetic medicine to make a profound difference in the lives of individuals living with rare genetic disease; and Sarepta being united with the global Duchenne community to do all possible to put an end to the damage caused by DMD.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its products to U.S. and ex-U.S. markets for various reasons, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta’s product candidates, the results of Sarepta’s ongoing research and development efforts and clinical trials for its product candidates may not be positive or consistent with prior results or demonstrate a safe treatment benefit, and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2017 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review Sarepta's 2017 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 iestepan@sarepta.com or

W2O GroupRachel Hutman, 301-801-5540rhutman@w2ogroup.com